BeiGene’s Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View

Citi initiated coverage on BeiGene Ltd (NASDAQ:BGNE) with a price target of $275 and a Buy stock rating.

The analyst notes that a detailed survey of 85 U.S. hematologists/oncologists suggests BeiGene’s flagship asset Brukinsa is positioned to become the favored BTK inhibitor for Chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow patients starting first-line therapy.